Handbook_Volume III

83 1. Aspetti Generali [14] Rambaldi A, Grassi A, Masciulli A, et al. Busulfan pluscyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16:1525–36 [15] Bacigalupo A, Raiola AM, Lamparelli T, Gualandi F, Occhini D,Bregante S, et al. Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up. Bone Marrow Transplant. 2007;40:1091–3 [16] BeelenDW,Trenschel R,Stelljes M et al.Treosulfan or busulfan plus fludarabine as conditioning treatmentbefore allogeneicHaemtopoietic stem cell transplantation for older patient wit acute myeloid leukemia or myelodysplastic syndrome (MC-FludT.14/L): a randomized, non-inferiority, phase 3 trial .Lancet Haematology 2020 Jan; 7(1):e28-e39 [17] Kolb HJ and Schmid C. The FLAMSA concept—past and future. Annals of Hematology (2020) 99:1979–1988 [18] McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–400 [19] Kharfan-Dabaja MA, Labopin M, Bazarbachi A, et al. Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant. 2014;49:1170–5 [20] Luznik L, O’Donnel PV,Symons HJ et al. HLA-haploidentical bone marrow transplantation for hematologic malignances using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide [21] Kröger N, Iacobelli S, Franke G-N, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial). J Clin Oncol. 2017;35(19):2157-2164 [22] Scott BL, Pasquini MC, Logan BR, et al.Myeloablative versus reduced-Intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35(11):1154-1161 [23] Blaise D, Tabrizi R, Boher J-M, et al.Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. Cancer. 2013;119(3):602-611 [24] Rashidi A, Meybodi MA, Cao W, et al.Myeloablative versus reduced-intensityhematopoietic cell transplantation inmyelodysplastic syndromes: systematicreview and meta-analysis. Biol BloodMarrow Transplant. 2020;26(6):e138-e141 [25] Rashidi A, Meybodi MA, Cao W, et al.Myeloablative versus reduced-intensity hematopoietic cell transplantation in myelodysplastic syndromes: systematic review and meta-analysis. Biol Blood Marrow Transplant. 2020;26(6):e138-e141 [26] Ma S, Shi W, Li Z, et al. Reduced-intensity versus myeloablative conditioning regimens for younger adults with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis. J Cancer. 2020;11(17):5223-5235 [27] Ringdén O, Labopin M, Ehninger G, et al.Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol. 2009;27(27):4570-4577 [28] Luger SM, Ringdén O, Zhang M-J, et al. Similar outcomes usingmyeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 2012;47(4):203- 211 [29] Bonifazi F, Rubio MT, Bacigalupo A et al. Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone Marrow Transplant 2020 Jun;55(6):1093-1102 [30] Carnevale-Scianca F,Caravelli D, Gallo S et al. Post-transplant cyclophosphamide and tacrolimus-mycophenolate mofetil combination prevents graft-versus-host disease in allogeneic peripheral blood hematopoietic cell transplantation from hla-matched donors. Biol Blood Marrow Transplant. 2017 Mar;23(3):459-466 [31] Chiusolo P,Bug G, Olivieri A et al. A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study. Biol Blood Marrow Transplant. 2018 Jun;24(6):1243-1249 [32] Mussetti A, Paviglianiti A, Parody R and Sureda a. Is post-transplant ciclophosphamide the new methotrexate ?. J Clin Med. 2021 Aug 12;10(16):3548 [33] W J Chng, A Dispenzieri, C-S Chim, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia volume 28, pages269–277 (2014) [34] Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, et al. Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Haematologica. 2018;103:514–21 [35] Vose JM, Carter S, Burns LJ, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31:1662–8 [36] Marchesi F, Capria S, Pedata M,et al. BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant..Leuk Lymphoma. 2020 Sep;61(9):2238-2241 [37] Hahn L, Lim H, Dusyk T et al. BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy. Sci Rep. 2021 Jul 7;11(1):14071